New Drug Approved for Lung Cancer

Gilotrif (afatinib) is now FDA approved for first-line treatment of metastatic non-small cell lung cancer with specific EGFR mutations.

Two new drugs for advanced melanoma!

Tafinlar and Mekinist are now approved for advanced malignant melanoma.  Tafinlar is approved for patients with the BRAF V600E gene mutation.  Mekinist is approved for patients with either the BRAF V600E or V600K gene mutations. 

Xofigo for Prostate Cancer

Xofigo (Ra223 dichloride) has been approved by the FDA for the treatment of metastatic castrate-resistant prostate cancer involving the bones only. 

Stivarga approved for GIST

Stivarga (regorafenib) has been approved for the treatment of GIST (GI stromal tumors) in patients with unresectable disease who have failed other treatments. 

Kadcyla now approved for HER positive breast cancer

Kadcyla (ado-trastuzumab emtansine) has been approved for the treatment of HER 2 positive metastatic breast cancer in patients who have not responded to Herceptin (trastuzumab) with chemotherapy. 

Pomalidomide is new drug for Multiple Myeloma

Pomalyst (pomalidomide) has been approved for the treatment of relapsed and/or refractory Multiple Myeloma in patients who have received 2 prior therapies including Revlimid and Velcade and have had disease progression on or within 60 days of completion of their last therapy. 

Generic Doxil to relieve shortage

The FDA has now approved the generic form of Doxil which should help relieve shortages of the brand-name medication.